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EXECUTIVE SUMMARY 
This Technical Support Document reviews synthesis issues that arise on the construction of a 
baseline natural history model. The intention is to cover both the absolute response to 
treatment on the outcome measures on which comparative effectiveness is defined, and also 
other elements of the natural history model, which are usually “downstream” of the shorter-
term effects reported in trials. 
It is recommended that the same Generalised Linear Modelling framework is used to model 
the absolute effects of a “standard treatment” or placebo comparator, as that proposed for 
synthesis of relative treatment effects in TSD2.1 Investigators should take care to justify their 
choice of data sources to inform the baseline, which could include a subset of the trials 
identified in the systematic review of relative effect data, cohort studies, patient registers, 
expert opinion, or combinations of these. It is suggested that the predictive distribution, rather 
than the fixed effect or random effects mean, is used to represent the baseline in order to 
reflect the observed variation in baseline rates. 
It is preferable to construct the baseline model independently from the model for relative 
treatment effects, in order to ensure that the latter are not affected by assumptions made about 
the baseline. However, simultaneous modelling of baseline and treatment effects could have 
some advantages, for example, when evidence is very sparse or when other research or study 
design give strong reasons for believing in a particular baseline model. Options for modelling 
effects of covariates, based either on aggregate or, preferably, individual patient data, or the 
use of risk equations for baselines, are also available. 
The natural history model beyond the (usually) shorter-term effects may also have parameters 
whose values are derived from synthesis. In the simplest and most easily interpretable 
models, the only effect of treatment is on the short-term outcomes and there is no 
independent effect of treatment on subsequent outcomes in the model. However, the evidence 
may not support this model structure. In this case, wherever possible, all parameters which 
take on different values for different treatments should be based on randomised data. Just as 
with the shorter term outcomes, great care should be taken in introducing non-randomised 
evidence that impacts directly on the between-treatment comparisons on later outcomes. 
Additionally the increased uncertainty and potential for bias should be addressed. 
Joint modelling of multiple baseline outcomes based on data from trials, or combinations of 
trial and observational data is recommended where possible, as this is likely to make better 
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use of available evidence, to produce more robust results, and to ensure that the model is 
internally coherent.  
Special synthesis methods for state transition models are available, that can be used to 
synthesise information from studies reporting state transitions at different follow-up times, 
results presented as either risks or rates, and information from incompletely observed state 
transitions. 
Finally, it is important to validate longer term predictions of the model against independent 
data wherever possible. There are several advantages to a multi-parameter synthesis approach 
to model validation and calibration, based on synthesis of the validating or calibrating data 
within the same model as the rest of the evidence. 
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1. INTRODUCTION 
Most cost-effectiveness analyses (CEAs) consist of two separate components: a baseline 
model that represents the absolute natural history under a standard treatment in the 
comparator set, and a model for relative treatment effects. The former may be based on trial 
or cohort evidence, while the latter is generally based on randomised controlled trial (RCT) 
data.2 The natural history under the new treatment is then obtained by putting together the 
baseline natural history model with the relative effect estimates based on the trial data. For 
example, if the probability of an undesirable event under standard care is 0.25 and the odds 
ratio for a given treatment compared to standard care is 0.8 (favouring the treatment), then, 
ignoring the uncertainty in these quantities, the absolute probability of an event on the 
treatment is p=0.21, obtained as 
 logit( ) logit(0.25) ln(0.8)p     
where logit(x)=ln(x/(1-x)) (see TSD21 for details). A similar approach can be used with 
models that are linear in log-relative risks or log-hazard rates (see TSD21). 
Usually, the role of trial data within an economic evaluation – whether to inform absolute or 
relative effects – is limited to the short- or intermediate-term outcomes. Health economists 
expend considerable effort in building the longer-term elements of the model, which often 
take the form of a Markov transition model where the relative treatment effects will be 
assumed to act on specific transitions.3 However, a wide range of modelling techniques may 
be utilised, apart from Markov models. “Mapping” from the shorter term outcomes, or from 
the Markov states into utilities is a further component of the model.3 
This Technical Support Document (TSD) focuses on the evidence synthesis issues that arise 
in construction of the natural history model, based on the general principles set out in the 
NICE Guide to Methods of Technical Appraisal.2 There is no attempt to give 
recommendations or guidance on principles of model construction, or on the type of model, 
except in so far as this might affect synthesis issues. Patient-level simulation models, where 
patients are tracked individually throughout the economic model, are outside the scope of this 
document, which is focused on evidence synthesis. Readers are referred to the literature for 
more details.3,4 
We begin, with the baseline model for the outcomes that have been compared in some form 
of comparative study (Section 2). For this purpose we borrow heavily from the generalised 
linear modelling framework developed in TSD2,1 since the exact same link functions and 
likelihoods used to analyse information on relative treatment effects can, and should, be 
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applied to synthesise the evidence on the baseline treatment. In this section we also devote 
some space to the question of what sources of evidence should be used for the baseline 
model, and also to potential linkage between baseline and relative effect models. 
Section 3 then examines synthesis issues that relate to the natural history model 
“downstream” of the trial data, that is how to inform parameters, other than relative treatment 
effects, required to inform the economic model. Typical parameters that require values could 
be as diverse as complication rates from the underlying condition, duration of hospital stay, 
duration of medication, natural history following cessation of treatment, incidence of side 
effects, relapse rates, mortality on and off treatment, “mappings” from surrogate to clinical 
end-points or from disease-specific measures to Quality of Life measures, and so on. As 
noted above, there is a wide range of model types and model structures that can be deployed. 
If state transition models are used, it is possible that the trial outcomes represent only the 
transition from one specific state to another, and that information on the remaining transitions 
will need to be sourced from elsewhere. Usually, identification of appropriate data to inform 
these parameters is likely to be more critical to the decision than technical issues of how to 
synthesise the evidence once it is selected.  
However, two specific issues deserve careful consideration. In the ideal case all predicted 
differences between treatments would originate from information from RCTs. This applies as 
much to the downstream outcomes as it does to the more immediate short-term outcomes 
which are usually based on RCT data. Any use of non-randomised data that has a direct 
bearing on between-treatment comparisons always needs careful consideration of potential 
bias2 (see also TSD35). Secondly, whether information on “downstream” outcomes is based 
on randomised or non-randomised data, there is a potential for conflict between the observed 
long-term relative effects and those predicted by the short-term and natural history models. 
We describe the issues and suggest possible approaches, although this area has not yet been 
adequately researched. 
Finally, Section 4 briefly reviews issues in model calibration and validation. In most accounts 
of validation, predictions of final outcomes from a model are compared with independent 
sources of data. “Calibration” is a process whereby estimates are modified in light of external 
data. A third possibility is an evidence synthesis approach, in which the model parameters are 
all estimated simultaneously using both the original sources of information and the 
independent data. Section 4 outlines properties of a synthesis approach to validation and 
calibration, and provides some references to these methods. 
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2. BASELINE MODELS FOR TRIAL OUTCOMES 
2.1. SOURCES OF EVIDENCE FOR BASELINE OUTCOMES 
Once a baseline (or reference) intervention has been defined (see TSD21), a reasoned protocol 
for systematic study search and inclusion should be developed,6-8 and potential sensitivity to 
alternative options explored, if appropriate. Since the baseline response should be as specific 
as possible to the population of interest,2,3 it may be more reasonable to use only evidence 
from recent trials, relevant cohort studies, register studies9 or, in certain cases, expert 
opinion.8 A common approach to identifying sources of evidence for baseline outcomes has 
been to use the same trials that have supplied information on relative effects, but restricting 
attention to the trials arms that use the baseline treatment. This is a possible approach, but 
needs to be justified in each case. Investigators should consider whether all the trials used to 
inform the relative effects can be considered as equally representative of the absolute 
response that would be obtained in the target population and under current circumstances, 
particularly if some of the trials were carried out many years ago or had very restrictive 
inclusion criteria. It is also possible to combine evidence from different types of relevant 
randomised and non-randomised studies.  
Whatever the source of evidence used to populate the decision model, this should be 
transparent and reported in sufficient detail to allow outside scrutiny.2,6,8,10 
 
2.2. SYNTHESIS OF AGGREGATE DATA ON BASELINE RESPONSE 
2.2.1. Separate models for baseline and treatment effect 
TSD21 introduced a Generalised Linear Modelling framework for synthesis of relative effect 
estimates. This can be expressed as: 
 ,1 { 1}( ) ik i i k kg I         
where 
 { }
1 if  is true
0 otherwiseu
u
I  

  
g() is the link function (for example the logit link), and ik  is the linear predictor, consisting 
of a trial-specific baseline effect in a trial i, μi (for example a log odds), and δi,1k a trial-
specific treatment effect of the treatment in arm k relative to the treatment in arm 1 (the log 
odds ratio). In the Bayesian framework adopted throughout these documents in models for 
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the relative treatment effect, the μi are given unrelated vague priors. To model baseline 
effects the following formulation can be adopted: 
 
2
( )
~ ( , )
ik i
i m
g
N m
  
 
 
  (1) 
in which the study-specific baselines are drawn from a distribution of effects with a common 
mean and variance. To complete the model, in a Bayesian framework, vague priors can be put 
on the mean and on the variance, for example 2~ (0,100 )m N , and ~ (0,5)m Uniform  or 
2 3 31/ ~ (10 ,10 )m Gamma
  .  
The proposal is, therefore, that a separate model is run to summarise the relevant baseline 
data. One option is to run this code at the same time as the model for the relative treatment 
effect, ensuring that the information in the baseline model does not propagate to the relative 
treatment effects model. This can be done in WinBUGS using the “cut” function.11 The 
advantage of this approach is that both models are contained in a single file and can be run 
simultaneously thereby ensuring that any new data added to the baseline model automatically 
updates the absolute effects generated from the relative effects model. It also ensures that the 
samples from the posterior distribution of the baseline effect are used directly. A simpler 
alternative is to run separate models, and then, assuming normality of the posterior 
distribution of the baseline effect, take the appropriate posterior summaries (the mean and 
uncertainty), and insert them into the relative effect code. This will of course rely on the 
approximate normality of the posterior distribution of the baseline effect – this should always 
be checked, but usually holds, in our experience. Alternatively, the samples from the 
posterior distribution of the baseline effect can be fed into the separate relative effects model.  
In each of the examples presented in the Appendix for TSD2,1 where WinBUGS code for 
various models and outcome types is given, results from a separate external analysis are 
“plugged in” to generate predictions for absolute response rates or probabilities. For 
illustrative purposes, the external analysis generated a predictive distribution of the baseline 
in a “new” study, based on a random effects model. Note that this is different from simply 
calculating the unweighted mean of the baseline arms in the relative effects model, an 
approach which is not recommended under any circumstances. 
The reasons for keeping the baseline and relative treatment effects models separate are to 
avoid the assumptions made on the baseline model affecting the relative treatment effects and 
because they are often based on different data sources. However, if there are strong reasons to 
believe in a particular baseline model, joint modelling of baseline and relative effects should 
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be considered (see Section 2.2.2). Issues related to correlation between outcomes and 
baseline by treatment interactions are discussed in TSDs 21 and 3,5 respectively. 
Program 1 in the Appendix to this document includes code which takes the 19 ‘No 
intervention’ arms from a smoking cessation dataset12 (see TSD4,13 Section 4.2.1), and 
implements the model in equation (1). 
There are two ways the results of this analysis can be used. The simplest approach is to use 
the posterior mean of m and its posterior standard deviation to represent the baseline 
response. But, it could be argued that this under-represents the variation observed in the data: 
if we were to gather more and more data on the baseline arm, our estimate of the mean would 
become more and more precise, but the variation would remain unchanged. An alternative, 
therefore, is to use the predictive distribution of a new baseline,  
 2 ~ ( , )new mN m   (2) 
where m and 2m  are sampled from the posterior distribution. This predictive distribution for 
a new baseline incorporates the uncertainty about the value a new observation might take, as 
well as the observed variation in the data. It is however important to ensure that the 
uncertainty conveyed by the predictive distribution reflects genuine uncertainty in the 
baseline. Therefore, we reiterate the need for careful evaluation of what studies should be 
used to inform the baseline model and whether the exchangeability assumption between the 
baseline effect in the included studies and the “new” baseline (equations (1) and (2)) holds. 
Both approaches are illustrated in the Appendix (Program 1). The first column of Table 1 
shows the results obtained in the smoking cessation example, using separate RE models for 
baseline and treatment effects. All results are based on 50,000 iterations from 3 independent 
chains, after discarding 20,000 burn-in iterations to ensure convergence. Using the posterior 
distribution of the mean produces a mean baseline smoking cessation probability of 0.07 with 
credible interval (0.05, 0.09). By contrast, if the predictive distribution is used, the mean is 
approximately the same but the wider credible interval (0.02, 0.20) better reflects the range of 
variation in the observed data, under the assumption of normally distributed random effects 
(Table 1).  
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Table 1 Posterior mean, standard deviation (sd) and 95% Credible Interval (CrI) of the mean and 
predictive log-odds of smoking cessation on ‘No contact’ (m and new), absolute probabilities of smoking 
cessation based on the posterior and predictive distributions of the baseline log-odds, and of the log-odds 
ratio of response relative to ‘No Contact’ (log-odds ratios > 0 favour the active treatment). Posterior 
median, sd and 95% CrI for the between-trial heterogeneity in baseline (m) and in treatment effects () 
for RE meta-analysis with separate or simultaneous baseline and treatment effects modelling; and 
measures of model fit: posterior mean of the residual deviance (resdev), effective number of parameters 
(pD) and DIC. 
 
Separate Models Simultaneous modelling 
 
mean/median sd 95% CrI mean/median sd 95% CrI 
 Baseline model parameters 
m -2.59 0.16 (-2.94,-2.30) -2.49 0.13 (-2.75,-2.25) 
m 0.54 0.16 (0.32,0.93) 0.45 0.11 (0.29,0.71) 
new -2.59 0.60 (-3.82,-1.41) -2.49 0.49 (-3.48,-1.52) 
 
Absolute probabilities of response based on the posterior 
distribution of the baseline probability 
No contact 0.07 0.01 (0.05,0.09) 0.08 0.01 (0.06,0.10) 
Self-help 0.12 0.05 (0.05,0.23) 0.13 0.04 (0.07,0.21) 
Individual Counselling 0.15 0.04 (0.09,0.24) 0.15 0.03 (0.11,0.21) 
Group Counselling 0.19 0.07 (0.08,0.37) 0.20 0.05 (0.11,0.31) 
 
Absolute probabilities of response based on the predictive 
distribution of the baseline probability 
No contact 0.08 0.05 (0.02,0.20) 0.08 0.04 (0.03,0.18) 
Self-help 0.13 0.08 (0.03,0.34) 0.14 0.07 (0.04,0.30) 
Individual Counselling 0.17 0.09 (0.05,0.39) 0.16 0.07 (0.06,0.33) 
Group Counselling 0.21 0.12 (0.05,0.50) 0.21 0.09 (0.07,0.43) 
 Relative treatment effects compared to ‘No contact’ 
Self-help 0.49 0.40 (-0.29,1.31) 0.53 0.33 (-0.11,1.18) 
Individual Counselling 0.84 0.24 (0.39,1.34) 0.78 0.19 (0.41,1.17) 
Group Counselling 1.10 0.44 (0.26,2.01) 1.05 0.34 (0.39,1.72) 
 0.82 0.19 (0.55,1.27) 0.71 0.13 (0.51,1.02) 
resdev* 54.1   47.4   
pD 45.0   40.1   
DIC 99.1   87.5   
* compare to 50 data points 
 
Note that the choice of posterior or predictive distribution will have very little effect on the 
differences between treatments, but the latter will contribute greater uncertainty in the natural 
history model. The probabilities of smoking cessation for the four treatments calculated using 
both the posterior and predictive uncertainties are shown in Table 1. Figure 1 illustrates the 
impact of the two approaches on the uncertainty in treatment effects, which results in the 
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wider credible intervals when the predictive distribution is used, representing the true level of 
uncertainty. 
 
 
Figure 1 Absolute probabilities of smoking cessation for all treatments with 95% CrI based on the 
posterior (filled squares, solid lines) and predictive distributions (open squares, dashed lines) of the mean 
log-odds for “No intervention” for separate RE models for the baseline and treatment effects. 
 
2.2.2. Simultaneous modelling of mean and treatment effects 
The separation of absolute and relative treatment effects may seem artificial. Nevertheless, it 
is the recommended method because it means that the treatment effects are unaffected by any 
assumptions made about the baseline. However, there may be reasons for modelling the 
baseline and treatment effects together. One reason would be that this can increase the 
stability of the model when there are zero cells (see TSD21, Section 6.3). Another may be 
that, based on other research, there are strong reasons for believing in a particular model for 
the baseline, for example when modelling results from cluster randomised14,15 or multicentre 
trials (whereas usually no model for baseline is assumed – see TSD21). 
To carry out such an analysis, it is only necessary to replace the “unrelated” priors for μi in 
the standard meta-analysis code presented in TSD2,1 with a “random effects” prior with a 
mean and variance, and to supply priors for the mean and between-study variance of the 
baseline effects. In a network meta-analysis where not all trials include the baseline 
No intervention
Self-help
Individual Counselling
Group Counselling
0 .1 .2 .3 .4 .5
Probability of Smoking Cessation
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(reference) treatment, it is necessary to ensure that the μi being modelled always refer to the 
baseline treatment, i.e. treatment 1. Note that simultaneous modelling of the baseline and 
treatment effects will have considerable impact on the relative effect estimates, and always 
needs to be justified. A sensitivity analysis to show the effect on the relative treatment effects 
should be carried out, if possible. WinBUGS code for simultaneous modelling of baseline 
and treatment effects is supplied in Program 2 in the Appendix. Once again, we would 
recommend that the predictive distribution of a “new” baseline (equation (2)) is taken 
forward for decision modelling.  
The second column in Table 1 shows the posterior and predictive probabilities of smoking 
cessation for the four treatments from a simultaneous model of baselines and treatment 
effects. Having a model that simultaneously estimates baseline and treatment effects greatly 
impacts on the estimated between-trial heterogeneity (posterior median of =0.82 for 
separate models and 0.71 in the joint model) and consequently on the uncertainty around the 
mean treatment effects. This in turn produces less uncertainty in the absolute treatment 
effects based on the predictive distribution.  
The heterogeneity in the observed baselines m is also smaller when modelling baseline and 
treatment effects simultaneously than when separate analyses are performed, which has an 
impact on the variability of the predictive distribution for the baseline, given by the standard 
deviation of new in Table 1. 
 
2.3. BASELINE MODELS WITH COVARIATES 
2.3.1. Using aggregate data 
Covariates may be included in the baseline model by including terms in the linear predictor. 
For a covariate C, which could either be a continuous covariate or a dummy covariate, we 
would have, for arm k of trial i 
 { 1}ik i i ik kC I          
An estimate of the covariate effect β, like the estimate of , could be obtained from the trial 
data or externally. Govan et al16 give an example where the covariate on the baseline is 
estimated from aggregate trial data with the purpose of reducing aggregation bias.17 This is a 
phenomenon in which the presence of a strong covariate, even if balanced across arms, and 
even if it is not a relative effect modifier, causes a bias in the estimation of the relative 
16 
 
treatment effects, towards the null. Govan et al16 also show a method for dealing with missing 
data on covariates. See TSD35 for further discussion. 
2.3.2. Risk Equations for the baseline model based on Individual Patient Data 
A far more reliable approach to informing a baseline model which expresses difference in 
baseline progression due to covariates such as age, sex, disease severity at onset of treatment, 
is to use individual patient data. This is considered superior to aggregate data as the 
coefficients can be estimated more precisely and with less risk of ecological bias. The results 
are often presented as “risk equations” based on multiple regression from large trial 
databases, registers, or cohort studies. Natural histories for each treatment are then generated 
by simply adding the treatment effects based on trial data to the risk equations as if they were 
another risk factor. The main difficulty facing the cost-effectiveness analyst here is in 
justifying the choice of data source and its relevance to the target population. Analyses 
should be presented that explore the different characteristics of the populations in these 
alternative studies, and their relation to the target population for the decision. If necessary, 
sensitivity analyses should be presented to show sensitivity of results to the choice of data 
source used to inform these parameters. 
 
3. SYNTHESIS ISSUES IN THE REST OF THE NATURAL HISTORY 
MODEL 
Choice of evidence sources and statistical model for the natural history model beyond the 
immediate short-term trial outcomes is beyond the scope of this document. However, we 
provide some comments on the origin of treatment differences, or implied treatment 
differences, in longer term outcomes, as this touches on synthesis issues, on the internal 
coherence of models and their consistency with the evidence. 
 
3.1. SOURCE OF INFORMATION FOR NATURAL HISTORY PARAMETERS AND 
IMPLICATIONS FOR RELATIVE TREATMENT EFFECTS 
Generally, the source of evidence used for each natural history parameter should be 
determined by a protocol driven review.2,6,8 Previous CEAs are an important source of 
information on the data sources that can inform natural history. 
17 
 
A common modelling strategy is to assume that there are no differences between treatments 
in the “downstream” model, conditional on the shorter term trial outcomes. We can call this 
the “single mapping hypothesis” as the implication is that, given information on the short-
term differences, longer-term differences can be obtained by a single mapping applicable to 
all treatments. For example, in a model to assess cost-effectiveness of various antiviral drugs 
for the treatment of influenza, the base-case analysis assumed that use of antivirals only 
affected short-term outcomes and had no additional impact on longer term complication and 
hospitalisation rates.18 Models with this property are attractive, although they make strong 
assumptions. The assumptions are natural if the alternative active comparators can be 
considered to be a single class, but may be less plausible if they are not. Such assumptions 
have to be justified clinically and physiologically, and for each outcome “mapped” available 
data, for example on length of hospital stay, time on treatment, complications rates, mortality, 
and all other downstream outcomes, should be reviewed, examined and interpreted. This 
review should also include the empirical and statistical literature on adequacy of surrogate 
outcomes, and in particular whether the evidence supports the view that treatment effects on 
the shorter-term “surrogate” translate into the same longer-term benefits for all treatments. 
This review might usefully extend beyond the class of products being considered, because the 
wider the range of treatment for which a “single mapping” hypothesis can be sustained, the 
more robust it is likely to be. Eventually, however, it may be decided that the relation 
between surrogate and clinical outcomes is only relevant for the subset of treatments within 
the decision. The use of “surrogate endpoint” arguments in health technology assessment 
(HTA) extends far beyond the outcomes classically understood as “surrogates” in the clinical 
and statistical literature.19 HTA literature makes frequent use of “mapping” from short-term 
to longer-term outcomes, as this allows modellers to base the modelled treatment differences 
on short term evidence. 
If the assumption that all downstream differences between treatments outcomes are due 
exclusively to differences in shorter term trial outcomes is not supported by the evidence, 
then the first option is to use available randomised evidence to drive longer-term outcomes. 
This necessarily implies different “mappings” for each treatment. 
The second and least preferred option is the use of non-randomised evidence. However, as 
with short-term outcomes, it is essential that any use of non-randomised data that directly 
impacts on differential treatment effects within the model is carefully justified, and that the 
increased uncertainty and the possibility of bias is recognised and addressed.2  
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3.2. JOINT SYNTHESIS OF MULTIPLE OUTCOMES TO INFORM NATURAL 
HISTORY 
The natural history model usually consists of a succession of “states” or sub-processes and 
involves a series of parameters which may impact on life-times costs, quality and length of 
life. It is preferable for these parameters to be estimated simultaneously from all the available 
data, as this is likely to allow more information to be incorporated and more validation to be 
carried out on the agreement between the model predictions and the evidence. The simplest 
examples of a coherent modelling of multiple outcomes are provided by the competing risk 
and the ordered probit analyses described in TSD21 (Sections 3.3 and 3.6, respectively). For 
example, use of the ordered probit model for the baseline and treatment effects guarantees 
coherent prediction of the probability that patients will achieve the different levels of 
response on categorical scales such as the PASI or ACR. By contrast, if ACR 20, ACR 50, 
and ACR 70 response are analysed separately, it is possible to end up with a model that 
makes impossible predictions, for example that more patients experience a 50% improvement 
on ACR than experience a 20% improvement. 
However, use of advanced modelling techniques may not have a substantial impact on cost-
effectiveness, and the usual approach in which each natural history parameter is sourced 
independently from data is more commonly adopted. 
Joint modelling of multiple trial outcomes to obtain the relative treatment effects has 
particular advantages, as is being seen increasingly in HTA. As well as reflecting a 
“coherent” view of the different outcomes, and correctly capturing the correlations between 
them, these methods address the frequently encountered problem of different outcomes being 
reported by different trials. The option of choosing a single outcome as the basis for the 
between-treatment comparison, may result in a high proportion of the information being 
discarded. It may be preferable, and lead to more robust results, if a model can be devised 
that expresses the relationships between the different outcomes, and thus allows all the 
evidence on treatment efficacy to be incorporated. Examples of models of treatment effects 
on multiple outcomes include treatment effects at multiple follow-up times,20,21 and 
multivariate models for continuous outcomes.22-24 It is also possible to synthesise two 
separate trial outcomes and parameters that link the outcomes, but which are based on 
observational data.25,26 
Somewhat more complex examples have arisen in the analysis of influenza treatments18,27 
which included a model of the relation between “time to end of fever” and “time to end of 
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symptoms”, or synthesis of outcomes on tumour response, time to progression and overall 
survival in advanced breast cancer.28,29 However, model structures vary across different 
diseases and, even within types of conditions, the structure of the evidence available to 
inform models can vary considerably. For these reasons it is difficult to provide general 
recommendations, other than to note that a single model encompassing several outcomes, as 
long as its assumptions are clear, and reflect a consensus view among clinical experts, is 
likely to provide a more robust basis for cost-effectiveness modelling.  
3.2.1. Synthesis of state transition models  
As with other natural history models, state transition model parameters may each be 
estimated independently from different sources, or they may be modelled jointly, although, as 
before, there are advantages in using methods that are capable of incorporating available 
information from all relevant sources. However, synthesis of state transition model 
parameters raises some special considerations because of the great variety of forms in which 
information is made available, for example: 
1. Data in study j may be reported as the probability of state transitions during a time 
interval Tj while the modeller may wish to use these data in a model with a cycle time T0. 
It is important to note that the standard adjustment30 is only valid for 2-state models. 
2. Information may be available on risks, or on rates. 
3. Information may be available on Hazard Ratios, but these cannot be easily converted into 
Relative Risks (or vice versa) in multi-state models, as the Relative Risk depends on the 
cycle time. 
4. Information may be available on state transitions from state A to state B, where 
individuals may have visited other states in between. This is sometimes referred to as an 
incompletely observed Markov process. 
Methods are available for synthesising a wide range of information on transitions, reported in 
different ways, over different time periods, and between different states in a model.31 Further, 
these methods can be used to simultaneously model natural history and treatment effect 
parameters,32 as before. Such methods also provide examples of a synthesis approach to 
calibration, described below. To date, these methods have all been limited to the case where 
all transition times are exponentially distributed. It remains to be seen how and under what 
conditions, the methods can be extended to other distributions. 
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4. MODEL VALIDATION AND CALIBRATION THROUGH MULTI-
PARAMETER SYNTHESIS 
Natural history models should be validated against independent data wherever possible. For 
example, in CEAs comparing a new cancer treatment to a standard comparator, the survival 
rates predicted in the standard arm could be compared to published survival rates, perhaps 
after suitable adjustment for age or other covariates. With other conditions, given an initial 
estimate of incidence or prevalence, together with statistics on the size of the population, the 
natural history model may deliver predictions on absolute numbers admitted to hospital with 
certain sequelæ, complications, or mortality. Once again these predictions could be checked 
against independent data to provide a form of validation. 
A more sophisticated approach is to use this external data to “calibrate” the natural history 
model. This entails changing the “progression rate” parameters within the model so that the 
model accurately predicts the independent calibrating data. Calibration, in a Bayesian 
framework particularly, can also be seen as a form of evidence synthesis.33 In this case the 
calibrating data is characterised as providing an estimate of a complex function of model 
parameters. This approach offers a remarkably simple form of calibration because, in 
principle, all that is required is that the investigator specifies the function of model 
parameters that the calibrating data estimates, and that a term for the likelihood for the 
additional data is added to the model. The information then propagates “backwards” through 
the model to inform the basic parameters. There are many advantages of this method over 
standard methods of calibration, which have recently been reviewed by Vanni et al:34 
1. it gives an appropriate weight to the calibrating data, taking account of sampling error; 
2. it avoids the “tweaking” of model parameters until they “fit” the calibrating data, a 
procedure that fails to capture the uncertainty in the data; 
3.  It avoids forcing the investigator to decide which of several natural history parameters 
should be changed (see below); 
4. Assessment of whether the validating data conflicts with the rest of the model and the 
data supporting it can proceed using standard model diagnostics, such as residual 
deviance, DIC, or cross-validation.1,5,25 
Examples of this approach have appeared in descriptive epidemiology35-38, and also in 
screening applications. In a model of early-onset neonatal group B streptococcus disease 
(EOGBS), the natural history model involved a series of parameters: probability of maternal 
carriage of group B streptococcus disease, probability of transmission to the newborn given 
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maternal carriage and probability of EOGBS given transmission. While information was 
available on each of these probabilities, the model was “calibrated” to data on the numbers of 
cases of EOGBS that had been reported in the British Isles through a paediatric clinical 
surveillance scheme.39 The effect of this form of calibration in this case is to put extremely 
weak constraints on the individual progression parameters, but to place quite strong 
constraints on their product. 
This kind of approach could potentially be applied in a number of clinical areas where 
independent data on long-term follow-up, registration of disease, or cause-specific mortality 
are available, though more research is needed before clear recommendations can be made. 
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APPENDIX: WINBUGS CODE FOR ILLUSTRATIVE EXAMPLES 
Below we set out code for a baseline model (Program 1) and a model which estimates 
baseline and treatment effects simultaneously (Program 2), with random effects, a binomial 
likelihood and logit link function. In TSD21 a generalised linear model framework was 
introduced, with explanations and examples of how the code for the binomial/logit model 
could be adapted for other likelihoods and link functions, including Poisson/log, 
Normal/identity and others. The baseline models below can be adapted in exactly the same 
way.  
All programming code is fully annotated. The code below is fully general and Program 2 will 
work for pairwise or network meta-analysis with any number of trials with any number of 
arms.  
The program codes are printed here, but are also available as WinBUGS system files from 
http://www.nicedsu.org.uk. Users are advised to download the WinBUGS files from the 
website instead of copying and pasting from this document. We have provided the codes as 
complete programs. However, the majority of the code for Program 2 is identical to program 
1(c) in TSD2,1 with new lines of code identical to code in Program 1, the separate baseline 
model. We have therefore highlighted the common lines of code between Programs 1 and 2, 
in blue and bold, to emphasise the modular nature of the code. 
PROGRAM 1. SMOKING CESSATION: BINOMIAL LIKELIHOOD, BASELINE RE 
MODEL WITH PREDICTIVE DISTRIBUTION 
# Binomial likelihood, logit link 
# Baseline random effects model 
model{     # *** PROGRAM STARTS 
for (i in 1:ns){    # LOOP THROUGH STUDIES 
    r[i] ~ dbin(p[i],n[i])   # Likelihood 
    logit(p[i]) <- mu[i]   # Log-odds of response 
    mu[i] ~ dnorm(m,tau.m)        # Random effects model  
  } 
mu.new ~ dnorm(m,tau.m)  # predictive dist. (log-odds) 
m ~ dnorm(0,.0001)                # vague prior for mean 
var.m <- 1/tau.m   # between-trial variance 
tau.m <- pow(sd.m,-2)     # between-trial precision = (1/between-trial variance) 
sd.m ~ dunif(0,5)                 # vague prior for between-trial SD 
} 
 
Absolute probabilities of response can be calculated for any treatment by inputting the 
estimates for baseline predictive mean and uncertainty from the analysis above (i.e. the 
posterior mean and variance obtained from monitoring mu.new) into the treatment effects 
model, as detailed in the Appendix to TSD2.1 
26 
 
Alternative prior distributions can be used for the baseline random effects variance (see 
TSD2,1 Section 6.2, for a discussion of prior distributions). For example, the last two lines of 
code in Program 1 can be replaced by a vague Gamma prior on the precision parameter, 
which is sometimes also referred to as a vague inverse Gamma prior on the variance: 
 
tau.m ~ dgamma(0.001,0.001) 
sd.m <- sqrt(var.m) 
 
Additional code can be added before the closing brace to estimate the probabilities of 
response on the baseline treatment, based on the posterior (R) or predictive (R.new) 
distributions of the mean baseline log-odds of response. 
 
logit(R) <- m                     # posterior probability of response 
logit(R.new) <- mu.new            # predictive probability of response 
 
The data structure has two components: a list specifying the number of studies ns and the 
main body of data in vector format, in the order r[] then n[], the numerators and denominators 
for all of the trial arms containing the baseline treatment. Both data components need to be 
loaded into WinBUGS for the program to run. 
 
# Data (Smoking Cessation: baseline arms only) 
list(ns=19)  # ns=number of studies 
 
r[] n[] # Study ID 
9 140 # 1 
75 731 # 3 
2 106 # 4 
58 549 # 5 
0 33 # 6 
3 100 # 7 
1 31 # 8 
6 39 # 9 
79 702 # 10 
18 671 # 11 
64 642 # 12 
5 62 # 13 
20 234 # 14 
0 20 # 15 
8 116 # 16 
95 1107 # 17 
15 187 # 18 
78 584 # 19 
69 1177 # 20 
END 
 
# Initial values 
#chain 1 
list(mu=c(0,0,0,0,0,   0,0,0,0,0,   0,0,0,0,0,   0,0,0,0), sd.m=1, m=0) 
#chain 2 
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list(mu = c(-1,-1,-1,-1,-1,   -1,-1,-1,-1,-1,   -1,-1,-1,-1,-1,   -1,-1,-1,-1), sd.m=2, m= -1) 
#chain 3 
list(mu = c(1,1,1,1,1,   1,1,1,1,1,   1,1,1,1,1,   1,1,1,1), sd.m = 0.5, m = 1) 
 
PROGRAM 2. SMOKING CESSATION: BINOMIAL LIKELIHOOD, SIMULTANEOUS 
BASELINE AND TREATMENT EFFECTS RE MODEL WITH PREDICTIVE 
DISTRIBUTION 
This code implements the simultaneous modelling of baseline and treatment effects described 
in Section 2.2.2. Inclusion of a model for the baseline effect has a strong impact on the 
posterior distributions of the relative treatment effect. Therefore, we do not recommend this 
model unless under very special circumstances, such as those discussed in Section 2.2.2. Use 
of this model should be justified in detail. 
 
# Binomial likelihood, logit link 
# Simultaneous baseline and treat effects model for multi-arm trials 
model{                                  # *** PROGRAM STARTS 
for(i in 1:ns){                         # LOOP THROUGH STUDIES 
    w[i,1] <- 0         # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0                # treatment effect is zero for control arm 
    mu[i] ~ dnorm(m,tau.m)      # model for trial baselines re treatment 1 
    for (k in 1:na[i]) {                # LOOP THROUGH ARMS 
        r[i,k] ~ dbin(p[i,k],n[i,k])    # binomial likelihood 
        logit(p[i,k]) <- mu[i] + delta[i,k]    # model for linear predictor 
        rhat[i,k] <- p[i,k] * n[i,k]    # expected value of the numerators  
        dev.NA[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))  #Deviance contribution including NAs 
            +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) 
        dev[i,k] <- dev.NA[i,k]*(1-equals(n[i,1],1))  #Deviance contribution with correction for NAs 
       } 
    resdev[i] <- sum(dev[i,1:na[i]])         #  summed residual deviance contribution for this trial 
    for (k in 2:na[i]) {                # LOOP THROUGH ARMS 
        delta[i,k] ~ dnorm(md[i,k],taud[i,k])   # trial-specific LOR distributions 
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k]  # mean of LOR distributions (with multi-arm trial correction) 
        taud[i,k] <- tau *2*(k-1)/k   # precision of LOR distributions (with multi-arm trial correction) 
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])  # adjustment for multi-arm RCTs 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1)   # cumulative adjustment for multi-arm trials 
      } 
  }    
totresdev <- sum(resdev[])             # Total Residual Deviance 
d[1]<-0            # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }  # vague priors for treatment effects 
sd ~ dunif(0,5)         # vague prior for between-trial SD 
tau <- pow(sd,-2)       # between-trial precision = (1/between-trial variance) 
mu.new ~ dnorm(m,tau.m)          # predictive dist. for baseline (log-odds) 
m ~ dnorm(0,.0001)         # vague prior for mean (baseline model) 
var.m <- 1/tau.m            # between-trial variance (baseline model) 
tau.m <- pow(sd.m,-2)      # between-trial precision = (1/between-trial variance) 
sd.m ~ dunif(0,5)           # vague prior for between-trial SD (baseline model) 
}                                        # *** PROGRAM ENDS          
 
Alternative prior distributions can be used for the baseline random effects variance as before. 
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Additional code can be added before the closing brace to produce estimates of absolute 
effects of each treatment based on the posterior or predictive distributions of the mean 
baseline log-odds of response for treatment 1 (the baseline/reference treatment). 
 
# Provide estimates of treatment effects T[k] on the natural (probability) scale based on posterior distr of baseline model  
# and T.new[k] based on predictive distr of baseline model 
for (k in 1:nt) {  
    logit(T[k]) <- m + d[k]   
    logit(T.new[k]) <- mu.new + d[k]   
  } 
 
The data structure is similar to that presented in TSD2.1 Briefly, ns is the number of studies in 
which the model is to be based, nt is the number of treatments, and in the main body of data 
r[,1] and n[,1] are the numerators and denominators for the first treatment; r[,2] and n[,2], the 
numerators and denominators for the second listed treatment; r[,3] and n[,3], the numerators and 
denominators for the third listed treatment; t[,1], t[,2] and t[,3] are the treatments being compared 
in the trial arms, and na[] gives the number of arms in the trial. Text is included after the hash 
symbol (#) for ease of reference to the original data source. 
No Contact was chosen as the baseline/reference treatment because it was the current 
practice. However, in this example some trials do not include the baseline treatment 1 (trials 
2 and 21 to 24 in the data list below). To ensure that the model is put on the correct baseline 
parameter mu, an extra arm containing treatment 1 was added to these trials, with r[,1]=NA and 
n[,1]=1 and the number of arms in the trial amended accordingly. 
 
# Data (Smoking Cessation) 
# nt=no. treatments, ns=no. studies 
list(nt=4,ns=24 ) 
 
r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] r[,4] n[,4] t[,1] t[,2] t[,3] t[,4] na[] # ID 
9 140 23 140 10 138 NA NA 1 3 4 NA 3 # 1 
NA 1 11 78 12 85 29 170 1 2 3 4 4 # 2 
75 731 363 714 NA NA NA NA 1 3 NA NA 2 # 3 
2 106 9 205 NA NA NA NA 1 3 NA NA 2 # 4 
58 549 237 1561 NA NA NA NA 1 3 NA NA 2 # 5 
0 33 9 48 NA NA NA NA 1 3 NA NA 2 # 6 
3 100 31 98 NA NA NA NA 1 3 NA NA 2 # 7 
1 31 26 95 NA NA NA NA 1 3 NA NA 2 # 8 
6 39 17 77 NA NA NA NA 1 3 NA NA 2 # 9 
79 702 77 694 NA NA NA NA 1 2 NA NA 2 # 10 
18 671 21 535 NA NA NA NA 1 2 NA NA 2 # 11 
64 642 107 761 NA NA NA NA 1 3 NA NA 2 # 12 
5 62 8 90 NA NA NA NA 1 3 NA NA 2 # 13 
20 234 34 237 NA NA NA NA 1 3 NA NA 2 # 14 
0 20 9 20 NA NA NA NA 1 4 NA NA 2 # 15 
8 116 19 149 NA NA NA NA 1 2 NA NA 2 # 16 
95 1107 143 1031 NA NA NA NA 1 3 NA NA 2 # 17 
15 187 36 504 NA NA NA NA 1 3 NA NA 2 # 18 
78 584 73 675 NA NA NA NA 1 3 NA NA 2 # 19 
29 
 
69 1177 54 888 NA NA NA NA 1 3 NA NA 2 # 20 
NA 1 20 49 16 43 NA NA 1 2 3 NA 3 # 21 
NA 1 7 66 32 127 NA NA 1 2 4 NA 3 # 22 
NA 1 12 76 20 74 NA NA 1 3 4 NA 3 # 23 
NA 1 9 55 3 26 NA NA 1 3 4 NA 3 # 24 
END 
 
# Initial values 
#chain 1 
list(sd=1, m=0, sd.m=1, d=c(NA,0,0,0), mu.new=0, mu=c(1,1,1,1,1,   1,1,1,1,1,   1,1,1,1,1,   1,1,1,1,1,   1,1,1,1)  ) 
#chain 2 
list(sd=1.5, m=2, sd.m=2, d=c(NA,2,1,2), mu.new=1, mu=c(-1,1,-1,1,-1,   2,1,-2,1,2,   1,1,2,1,-2,   1,2,1,-2,1,   1,2,1,2)  ) 
#chain 3  
list(sd=3, m=.5, sd.m=.5, d=c(NA,-2,5,-5), mu.new=-1, mu=c(-1,5,-3,1,-1,   5,1,2,3,2,   1,5,2,1,-5,   1,2,-5,-3,1,   5,2,1,-5)  ) 
 
 
 
